Table 2.
Clinical stages of all patients
| Clinical stage | Overall cohort (n = 214) |
Derivation set (n = 150) |
Test set (n = 64) |
p value |
|---|---|---|---|---|
| BCLC | 0.050 | |||
| 0 | 31 (14.5) | 23 (15.3) | 8 (12.5) | |
| A | 105 (49.1) | 80 (53.3) | 25 (39.1) | |
| B | 33 (15.4) | 17 (11.3) | 16 (25.0) | |
| C | 45 (21.0) | 30 (20.0) | 15 (23.4) | |
| HKLC | 0.205 | |||
| I | 116 (54.2) | 86 (57.3) | 30 (46.9 | |
| IIa | 1 (0.5) | 1 (0.7) | 0 (0.0) | |
| IIb | 45 (21.0) | 30 (20.0) | 15 (23.4) | |
| IIIa | 1 (0.5) | 1 (0.7) | 0 (0.0) | |
| IIIb | 49 (22.9) | 32 (21.3) | 17 (26.6) | |
| IVa | 2 (0.9) | 0 (0.0) | 2 (3.1) | |
| JIS score | 0.301 | |||
| 0 | 27 (12.6) | 20 (13.3) | 7 (10.9) | |
| 1 | 102 (47.7) | 76 (50.7) | 26 (40.6) | |
| 2 | 55 (25.7) | 35 (23.3) | 20 (31.3) | |
| 3 | 29 (13.6) | 19 (12.7) | 10 (15.6) | |
| 4 | 1 (0.5) | 0 (0.0) | 1 (1.6) | |
| AJCC TNM | 0.142 | |||
| IA | 31 (14.5) | 23 (15.3) | 8 (12.5) | |
| IB | 97 (45.3) | 73 (48.7) | 24 (37.5) | |
| II | 37 (17.3) | 26 (17.3) | 11 (17.2) | |
| IIIA | 35 (16.4) | 21 (14.0) | 14 (21.9) | |
| IIIB | 12 (5.6) | 7 (4.7) | 5 (7.8) | |
| IVA | 2 (0.9) | 0 (0.0) | 2 (3.1) |
Data are expressed as n (%)
BCLC, Barcelona Clinic Liver Cancer; HKLC, Hong Kong Liver Cancer; JIS, Japan Integrated Staging; AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis